Skip to main content
. 2017 Jul 6;8(45):79662–79669. doi: 10.18632/oncotarget.19030

Figure 1. Progression-free survival of patients in the standard-dose group (50 or 50.4 Gy) and high-dose group (≥ 59.4 Gy).

Figure 1